SAGE

Shaking Things Up at Sage: Board Changes and Exploration Permits

Exciting updates from Sage Therapeutics and Sage Potash! Find out about the latest developments in the biopharmaceutical world.

Sage Therapeutics and Sage Potash are making headlines with recent announcements. Sage Therapeutics, a biopharmaceutical company focused on better brain health, has revealed changes to its Board of Directors. Kevin Starr's retirement marks a significant shift in leadership at the company known for its innovative approach. Meanwhile, Sage Potash Corp. has secured permit approvals for its exploration program, a crucial step in their journey towards new discoveries.

In another development, Sage Therapeutics is set to provide business updates at the 42nd Annual Conference. The company's commitment to enhancing brain health continues to drive its success and position in the market. With a focus on innovation and groundbreaking research, Sage Therapeutics remains a key player in the biopharmaceutical industry.

These recent events signal an exciting time for both companies as they navigate the challenges and opportunities in their respective fields. The strides made by Sage Therapeutics and Sage Potash underscore their dedication to advancements in healthcare and exploration.

In conclusion, the retirement of Kevin Starr from Sage Therapeutics' Board of Directors highlights the evolving landscape of leadership within the company. On the other hand, Sage Potash's receipt of all required permit approvals signifies a promising phase for their exploration program, hinting at potential breakthroughs in their sector.